Tenax Therapeutics, Inc. (TENX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tenax Therapeutics, Inc. on June 26, 2026. The filing details corporate governance actions taken by the Board of Directors regarding executive compensation and employee benefit plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation matters rather than financial performance.
Material Changes
- Executive Employment Amendments: The Board approved amendments to the employment agreements of Christopher Giordano (CEO), Thomas Staab, and Stuart Rich. These amendments align their severance and change-in-control benefits with the newly adopted company-wide plans.
- Adoption of New Plans: The Board adopted the Tenax Therapeutics, Inc. Change in Control (CIC) Plan and the Severance Plan for eligible employees (excluding the named executives).
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, market outlook, or discussion of operational risks. Management commentary is limited to the rationale for aligning executive compensation with the new employee benefit structures.
Compensation Structure Details
- Terminations Not in Connection with a Change in Control: Executives are entitled to 12 months of base salary plus one additional month per completed year of service (capped at 12 additional months), a pro-rated annual bonus, and 12 months of COBRA benefits. Dr. Rich also receives accelerated vesting of all equity awards.
- Terminations in Connection with a Change in Control: Executives receive 12 months of base salary (18 months for Mr. Giordano), a full annual bonus, accelerated vesting of all equity awards, and 12 months of COBRA benefits (18 months for Mr. Giordano).
- Employee Plans: The CIC Plan provides "double trigger" equity acceleration and cash severance for eligible employees upon termination without Cause or for Good Reason within a specific window surrounding a Change in Control. The Severance Plan provides similar cash benefits for terminations without Cause outside of a Change in Control.
Investor Verification Checklist
- Verify the specific terms of the "Change in Control" and "Good Reason" definitions in the full text of the CIC Plan and Severance Plan.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 to confirm the exact vesting schedules and bonus calculation methodologies for the named executives.
- Confirm the total number of eligible employees under the new CIC and Severance Plans to assess potential future cash outflows.
- Check subsequent filings for any actual terminations or change-in-control events that would trigger these new provisions.